These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 12543662)

  • 21. Aspergillus fumigatus CYP51 sequence: potential basis for fluconazole resistance.
    Edlind TD; Henry KW; Metera KA; Katiyar SK
    Med Mycol; 2001 Jun; 39(3):299-302. PubMed ID: 11446535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding.
    Xiao L; Madison V; Chau AS; Loebenberg D; Palermo RE; McNicholas PM
    Antimicrob Agents Chemother; 2004 Feb; 48(2):568-74. PubMed ID: 14742211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
    Mellado E; Garcia-Effron G; Alcázar-Fuoli L; Melchers WJ; Verweij PE; Cuenca-Estrella M; Rodríguez-Tudela JL
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1897-904. PubMed ID: 17371828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aspergillus fumigatus Clinical Isolates Carrying CYP51A with TR34/L98H/S297T/F495I Substitutions Detected after Four-Year Retrospective Azole Resistance Screening in Brazil.
    Pontes L; Beraquet CAG; Arai T; Pigolli GL; Lyra L; Watanabe A; Moretti ML; Schreiber AZ
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High prevalence of triazole resistance in clinical Aspergillus fumigatus isolates in a specialist cardiothoracic centre.
    Abdolrasouli A; Scourfield A; Rhodes J; Shah A; Elborn JS; Fisher MC; Schelenz S; Armstrong-James D
    Int J Antimicrob Agents; 2018 Nov; 52(5):637-642. PubMed ID: 30103005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspergillus fumigatus harbouring the sole Y121F mutation shows decreased susceptibility to voriconazole but maintained susceptibility to itraconazole and posaconazole.
    Lescar J; Meyer I; Akshita K; Srinivasaraghavan K; Verma C; Palous M; Mazier D; Datry A; Fekkar A
    J Antimicrob Chemother; 2014 Dec; 69(12):3244-7. PubMed ID: 25125676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three-dimensional models of 14α-sterol demethylase (Cyp51A) from Aspergillus lentulus and Aspergillus fumigatus: an insight into differences in voriconazole interaction.
    Alcazar-Fuoli L; Cuesta I; Rodriguez-Tudela JL; Cuenca-Estrella M; Sanglard D; Mellado E
    Int J Antimicrob Agents; 2011 Nov; 38(5):426-34. PubMed ID: 21871783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative Analysis of Single-Nucleotide Polymorphism for Rapid Detection of TR34/L98H- and TR46/Y121F/T289A-Positive Aspergillus fumigatus Isolates Obtained from Patients in Iran from 2010 to 2014.
    Mohammadi F; Hashemi SJ; Zoll J; Melchers WJ; Rafati H; Dehghan P; Rezaie S; Tolooe A; Tamadon Y; van der Lee HA; Verweij PE; Seyedmousavi S
    Antimicrob Agents Chemother; 2016 Jan; 60(1):387-92. PubMed ID: 26525787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Characterization of a Voriconazole-Resistant, Posaconazole-Susceptible Aspergillus fumigatus Isolate in a Lung Transplant Recipient in the United States.
    Vazquez JA; Manavathu EK
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1129-33. PubMed ID: 26574014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relation of the polymorphism of cyp51A sequence and the susceptibility of Aspergillus fumigatus isolates to triazoles determined by commercial gradient test (Etest) and by reference methods.
    Nawrot U; Sulik-Tyszka B; Kurzyk E; Mroczyńska M; Włodarczyk K; Wróblewska M; Basak GW; Brillowska-Dąbrowska A
    Acta Biochim Pol; 2017; 64(4):631-634. PubMed ID: 29202140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. cyp51A-based mechanism of azole resistance in Aspergillus fumigatus: Illustration by a new 3D Structural Model of Aspergillus fumigatus CYP51A protein.
    Liu M; Zheng N; Li D; Zheng H; Zhang L; Ge H; Liu W
    Med Mycol; 2016 May; 54(4):400-8. PubMed ID: 26768370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concomitant occurrence of itraconazole-resistant and -susceptible strains of Aspergillus fumigatus in routine cultures.
    Ahmad S; Joseph L; Hagen F; Meis JF; Khan Z
    J Antimicrob Chemother; 2015 Feb; 70(2):412-5. PubMed ID: 25326091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surveillance for azole resistance in clinical and environmental isolates of Aspergillus fumigatus in Australia and cyp51A homology modelling of azole-resistant isolates.
    Talbot JJ; Subedi S; Halliday CL; Hibbs DE; Lai F; Lopez-Ruiz FJ; Harper L; Park RF; Cuddy WS; Biswas C; Cooley L; Carter D; Sorrell TC; Barrs VR; Chen SC
    J Antimicrob Chemother; 2018 Sep; 73(9):2347-2351. PubMed ID: 29846581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus.
    Fraczek MG; Bromley M; Buied A; Moore CB; Rajendran R; Rautemaa R; Ramage G; Denning DW; Bowyer P
    J Antimicrob Chemother; 2013 Jul; 68(7):1486-96. PubMed ID: 23580559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of Aspergillus fumigatus and a mutation that confers reduced susceptibility to itraconazole and posaconazole by real-time PCR and pyrosequencing.
    Trama JP; Mordechai E; Adelson ME
    J Clin Microbiol; 2005 Feb; 43(2):906-8. PubMed ID: 15695702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Examination of cyp51A and cyp51B expression level of the first Polish azole resistant clinical Aspergillus fumigatus isolate.
    Brillowska-Dąbrowska A; Mroczyńska M; Nawrot U; Włodarczyk K; Kurzyk E
    Acta Biochim Pol; 2015; 62(4):837-9. PubMed ID: 26636140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of Polish clinical Aspergillus fumigatus isolates resistant to triazoles.
    Nawrot U; Kurzyk E; Arendrup MC; Mroczynska M; Wlodarczyk K; Sulik-Tyszka B; Wróblewska M; Ussowicz M; Zdziarski P; Niewinska K; Brillowska-Dabrowska A
    Med Mycol; 2018 Jan; 56(1):121-124. PubMed ID: 28340159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China.
    Zhang H; Tan J; Kontoyiannis DP; Zhou Y; Liu W; Zhu P; Shi X; Wan Z; Li R; Liu W
    Diagn Microbiol Infect Dis; 2019 Oct; 95(2):166-170. PubMed ID: 31174994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crystal Structure of the New Investigational Drug Candidate VT-1598 in Complex with Aspergillus fumigatus Sterol 14α-Demethylase Provides Insights into Its Broad-Spectrum Antifungal Activity.
    Hargrove TY; Garvey EP; Hoekstra WJ; Yates CM; Wawrzak Z; Rachakonda G; Villalta F; Lepesheva GI
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Azole resistance among clinical isolates of Aspergillus fumigatus in Lima-Peru.
    Bustamante B; Illescas LR; Posadas A; Campos PE
    Med Mycol; 2020 Jan; 58(1):54-60. PubMed ID: 31329931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.